Thierry Schmitz

The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery

Within this study, the potential of three clinically relevant microproteins (SE–AG–AZ, SE–EM and SE–EP) with cystine-knot architecture as pharmacophoric scaffolds for oral peptide delivery was investigated. Cystine-knot microproteins (CKM) were analysed regarding their stability towards the most important gastrointestinal secreted and membrane bound proteases in physiological concentrations. In addition, their permeation behaviour through freshly excised rat intestinal mucosa as well as important parameters such as aggregation behaviour, stability in rat plasma and isoelectric point were evaluated and compared to the properties of the model peptide drugs bacitracin and insulin. Aggregation studies indicate that under physiological conditions between 25 and 70% of the CKMs occur as monomers, whereas the rest forms di- and trimers. Pepsin and elastase cause no or only minor degradation to CKMs, whereas trypsin and chymotrypsin degrade CKMs extensively. Removing the theoretical chymotrypsin cleavage site from a CKM, however, led to stabilization towards this protease. Two of the three evaluated CKMs are stable against membrane bound proteases. Papp values were determined to be 5.96 ± 0.98 × 10− 6 and 6.63 ± 0.47 × 10− 6 cm/s. In conclusion, this study indicates that CKM are promising novel pharmacophoric scaffolds for oral peptide delivery.

Chitosan-N-acetyl cysteine conjugates: in vitro evaluation of permeation enhancing and P-glycoprotein inhibiting properties.

This study evaluated three chitosan-N-acetyl cysteine (CAC) conjugates of increasing molecular mass as a valuable tool to improve the absorption of drugs by assessing its permeation enhancing effect regarding the active P-gp substrate rhodamine-123 in comparison to the trans- and paracellular marker FD 4 both in rat intestine and Caco 2 monolayers. Additional LDH and MTT cytotoxicity tests have attested a non-toxic profile to CAC, which can consequently be seen as a safe and promising novel drug carrier with the ability to enhance drug absorption and to inhibit P-gp efflux transporters.

Characterisation of the thiol–disulphide chemistry of desmopressin by LC, μ-LC, LC-ESI-MS and Maldi-Tof

Summary.To date, the majority of therapeutic peptides and proteins have to be administered via parenteral routes, which are painful and inconvenient. In order to gain sufficient high blood concentrations after oral application, various barriers in the gastrointestinal tract have to be overcome. Apart from a poor membrane uptake and intense enzymatic degradation, this study will demonstrate that thiol–disulphide reactions are an underestimated essential part of the presystemic metabolism. Glutathione, integrative part of the antioxidant defence system in the gastrointestinal tract, may play an important role in the inactivation of orally given peptides and proteins. In order to verify this hypothesis, desmopressin which bears a single disulphide bond was used as model peptide drug. Desmopressin was incubated with GSH in various concentrations, and the extent of thiol/disulphide exchange reactions between the peptide drug and GSH was investigated in dependence on pH and ratio of reactants determined as a function of time via HPLC, LC-MS and Maldi-Tof-MS analyses.Results showed that desmopressin is degraded by 1% reduced glutathione at pH 4 and pH 5.5. In presence of 0.01%, 0.1% and 1% of reduced glutathione 6.1%, 19.4% and 52.1% of desmopressin, respectively, were degraded. The masses of the conjugates after deconvolution measured by liquid chromatography and electrospray ionisation mass spectrometric detection were m/z 1069.67, m/z 1376.50, m/z 1683.40 and m/z 2138. These molecular masses, confirmed by Maldi-Tof-MS analysis, correspond with the masses of conjugates expected in theory. Under defined conditions, these results reveal that thiol–disulphide exchange reactions have a considerable impact on the alteration of peptide drugs and proteins.

Oral peptide delivery: Are there remarkable effects on drugs through sulfhydryl conjugation?

In oral peptide delivery, the gap between convenient administration and low blood concentration has to be minimized. We found that oral peptide drugs have not only to pass the various commonly known barriers encountered with the gastrointestinal tract but that these drugs, under certain conditions, have also to be seen as redox partners for thiol bearing substrates. The interaction of glutathione (GSH) with peptides via thiol–disulfide exchange reactions was investigated for three peptides, vasotocin, oxytocin and octreotide. The extent of thiol–disulfide exchange reactions was investigated by liquid chromatography (LC) and further confirmed by hyphenation to electrospray ionization (ESI) and MALDI-TOF mass spectrometry (MS). We found that the presence of aromatic amino acid residues in the neighbourhood of the disulfide bond minimizes the thiol–disulfide interaction: oxytocin was degraded more than 80% with 1% reduced glutathione at pH 3.0 and vasotocin more than 40% under the same conditions. In the case of octreotide no interaction with GSH was observed. The obtained results revealed that thiol–disulfide exchange reactions have an important impact on the alteration of peptide drugs and proteins in the gastrointestinal tract.